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Abstract
Background: Given mounting evidence for adverse effects from excess manganese exposure, it is critical to
understand host factors, such as genetics, that affect manganese metabolism.
Methods: Archived blood samples, collected from 332 Mexican women at delivery, were analyzed for manganese.
We evaluated associations of manganese with functional variants in three candidate iron metabolism genes: HFE
[hemochromatosis], TF [transferrin], and ALAD [δ-aminolevulinic acid dehydratase]. We used a knockout mouse
model to parallel our significant results as a novel method of validating the observed associations between
genotype and blood manganese in our epidemiologic data.
Results: Percentage of participants carrying at least one copy of HFE C282Y, HFE H63D, TF P570S, and ALAD K59N
variant alleles was 2.4%, 17.7%, 20.1%, and 6.4%, respectively. Percentage carrying at least one copy of either C282Y
or H63D allele in HFE gene was 19.6%. Geometric mean (geometric standard deviation) manganese concentrations
were 17.0 (1.5) μg/l. Women with any HFE variant allele had 12% lower blood manganese concentrations than
women with no variant alleles (b = -0.12 [95% CI = -0.23 to -0.01]). TF and ALAD variants were not significant
predictors of blood manganese. In animal models, Hfe-/- mice displayed a significant reduction in blood
manganese compared with Hfe+/+ mice, replicating the altered manganese metabolism found in our human
research.
Conclusions: Our study suggests that genetic variants in iron metabolism genes may contribute to variability in
manganese exposure by affecting manganese absorption, distribution, or excretion. Genetic background may be
critical to consider in studies that rely on environmental manganese measurements.
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Background
Manganese (Mn) is an essential nutrient but also a
known neurotoxicant at high chronic exposure levels. In
particular, occupational studies have documented
adverse effects on motor, psychological, and neurological
function following long term exposures in adults, with
progressively worse symptoms persisting long after ces-
sation of exposure [1-6]. While most epidemiologic
literature on manganese toxicity has focused on occupa-
tional exposure, there is emerging evidence that elevated
environmental levels of manganese may cause cognitive
and motor deficits, as well as behavioral problems,
among both adults and children [7-15]. High maternal
blood manganese levels have also been associated with
lower birth weights, although this effect appears non-
linear [16].
Given the emerging evidence for adverse effects from
excess manganese exposure, it is critical to understand
host factors that affect manganese metabolism. Such fac-
tors may provide mechanistic clues for future
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interventions or may identify susceptible subpopulations.
For example, there is a well-known inverse association
between iron stores and manganese absorption. In
laboratory animals, iron deficiency results in increased
absorption and retention of manganese in various
organs [17-21]. Iron overload, in contrast, reduces man-
ganese accumulation in the brain and in other organs
[20]. In humans, similar inverse associations of blood
manganese with ferritin and dietary intake of nonheme
iron have been reported [22-24]. It is therefore likely
that iron and manganese share the same transport and
regulatory proteins, and at least one factor, Divalent
Metal Transporter-1 (DMT1), is known to mediate
uptake of both cations [25].
Manganese and iron are both transition metals and,
given their similar chemical properties, likely share
genetic factors that regulate their metabolism. Such
genetic factors may alter manganese absorption, excre-
tion, or tissue/cellular distribution, thereby altering
blood manganese levels. Variants of iron metabolism
genes with known functional properties, such as the
HFE gene, may be good candidates to regulate manga-
nese metabolism. The HFE gene product regulates levels
of the regulatory hormone hepcidin, thereby controlling
iron absorption in response to body iron status. Two
well-characterized, functional missense variants in the
HFE gene, C282Y and H63D, have been associated with
increased dietary iron uptake [26,27]. The C282Y variant
is the primary cause of the common form of hereditary
hemochromatosis, a genetic disease of excess iron
absorption. Transferrin is an iron transport protein that
delivers iron from the gastrointestinal tract to tissues. A
common missense variant in the TF (transferrin) gene,
P570S (or TFC2), has been associated with differential
binding of iron to transferrin relative to the wildtype
protein [28]. Finally, ALAD (δ-aminolevulinic acid dehy-
dratase) is part of the heme synthesis pathway [29].
Heme is a necessary component of hemoglobin and all
cytochrome enzymes, and requires iron for enzyme
activity. This iron metabolism gene has been linked to
metal toxicity [30-32] as well as metal binding [33]. The
K59N (or ALAD2) variant of this gene has also been
associated with increased hemoglobin [34]. We hypothe-
sized that, because each of these iron metabolism genes
has common functional variants and because iron meta-
bolism is linked to manganese metabolism, these var-
iants may be associated with altered blood manganese
levels. We also explored whether any observed effects of
genotype are mediated through iron status.
We examined these questions using blood manganese
levels in a cohort of women at time of delivery. Preg-
nancy is a time at which blood manganese levels
increase [35,36] as well as a time of relative iron defi-
ciency. We believed the increase in variability of both
iron stores and blood manganese would increase our
ability to detect differences in blood manganese related
to genetic variants in iron metabolism genes. This time
point is also relevant because maternal blood manganese
is a measure of prenatal exposure to the fetus, and there
is evidence that environmental manganese exposure in
utero is associated with later life behavioral disinhibition
[9] and lower psychomotor development test scores
among offspring [12]. Cost constraints prevented a large
scale or full interrogation of the iron metabolism gene
pathway. Instead, we focused specifically on three candi-
date iron metabolism genes, HFE, TF, and ALAD, which
have either known or putatively functional variants. In
order to validate that our findings were not due to
chance or linkage disequilibrium (LD) with a nearby
functional variant, we used a knockout mouse model to
determine if we could replicate our results in an experi-
mental setting. This is a novel method of validating
observed associations involving genetics and observa-
tional epidemiologic data. It is not subject to population
substructure and is more cost effective than replicating
findings in an independent population. To our knowl-
edge, this is also the first study to examine blood man-
ganese levels in HFE-deficient mice.
Methods
Study participants
The human subjects committees of the National Insti-
tute of Public Health of Mexico, Harvard School of Pub-
lic Health, and participating hospitals approved all study
materials and procedures. Study participants were iden-
tified from among pregnant women who were eligible to
participate in a randomized trial of calcium supplemen-
tation to lower blood lead levels among postpartum lac-
tating women [37]. Women were recruited for this trial
between January 1994 and June 1995 from three mater-
nity hospitals in Mexico City that serve a low- to mod-
erate-income population. Data collection and exclusion
criteria are detailed elsewhere [38]. Briefly, women were
excluded due to: factors that could interfere with mater-
nal calcium metabolism; logistic reasons that would
interfere with data collection; intention not to breast-
feed; and certain medical conditions.
Demographic and social characteristics were collected
from women within 12 hours of delivery. For the trial,
venous blood samples were collected for lead measure-
ment, genotyping, and iron status (i.e., serum ferritin
and hemoglobin, when possible) at or near the time of
delivery. From a total of 614 women eligible for rando-
mization, 571 were successfully genotyped (4 samples
were excluded due to blood data collection errors). The
availability of blood for DNA extraction was given prior-
ity; therefore, the blood sample with the higher volume
was chosen for DNA extraction/genotyping. Any
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remaining blood was archived and subsequently ana-
lyzed for manganese for use in the present analysis.
Three hundred thirty-two (54 percent) had archived
blood samples from delivery still available for measure-
ment of manganese concentration. Manganese does not
degrade; therefore, our results should not be affected by
storage. Because we measured blood manganese at time
of delivery, our data predate the calcium intervention
trial and the randomization process cannot affect our
results. At 1-month postpartum, additional blood sam-
ples were collected for hemoglobin and ferritin
measurement.
Genotyping
High-molecular-weight DNA was extracted from white
blood cells with commercially available PureGene Kits
(Gentra Systems, Minneapolis, MN). After DNA quanti-
fication, samples were adjusted to TE buffer, partitioned
into aliquots, and stored at -80°C. To design multiplex
PCR assays, we used Sequenom SpectroDESIGNER soft-
ware and inputted sequence containing the SNP and
100 bp of flanking sequence on either side of the SNP.
Four SNPs were multiplexed: (HFE) C282Y (rs1800562)
and (HFE) H63D (rs1799945), transferrin (TF) P570S
(rs1049296), and δ-aminolevulinic acid dehydratase
(ALAD) K59N (rs1800435). The extension product was
then spotted onto a 384-well spectroCHIP before being
flown in the MALDI-TOF mass spectrometer. Reference
sequences and primers used in the multiplex assay are
provided in Additional file 1.
Measurement of blood manganese
Blood samples were collected in trace metal-free tubes
at delivery from all participants and immediately frozen.
Because blood manganese levels change over the course
of pregnancy [35,36], it was necessary to collect samples
at approximately the same time point for all women.
We chose samples from delivery, which also avoids any
influence from the calcium trial. Blood samples were
prepared and analyzed for manganese concentrations at
the Trace Metals Laboratory at Harvard School of Pub-
lic Health in Boston, MA. Metals concentrations were
measured with a dynamic-reaction cell-inductively-
coupled plasma mass spectrometer (DRC-ICP-MS, Elan
6100, Perkin Elmer, Norwalk, CT), using previously
described methods and quality control measures [16]. In
short, blood samples were weighed (1 g) and digested in
HNO3 acid, followed by addition of H2O2 at room tem-
perature, and then diluted with deionized water. Quality
control measures included initial and continuous cali-
bration verification standards, procedural blanks, dupli-
cate samples, spiked samples, and the National Institute
of Standards and Technology Standard Reference Mate-
rial for trace elements in water (NIST SRM 1643d).
Although iron may cause interference of the manganese
measurement on ICP-MS, due to the high concentration
of iron (54Fe) and its proximity to manganese (55Mn) on
the periodic table, any potential interference is not
expected to change the rankings of blood manganese
levels in our samples. Recovery rates for manganese in
quality control samples were 83%-100%, and precision
(%RSD) was less than 10%. The average limit of detec-
tion was 0.09 μg/dl.
Blood manganese in HFE-deficient mice
Animal protocols were approved by the Harvard Medi-
cal Area Animal Care and Use Committee. HFE-defi-
cient (Hfe-/-) and “wildtype” control (129/SvEv; Hfe+/+)
mice were kindly provided by Dr. Nancy Andrews
(Duke University) to establish a breeding colony. Mice
were maintained on a 12-h light/dark cycle and con-
sumed a facility chow containing 220 mg/kg iron (Pico-
Lab 5058, PharmaServ) and water ad libitum. The
mutation involved in the Hfe-/- phenotype was verified
by PCR as described by Levy et al. [39]. At four months
of age (young adult; considered to be comparable in age
to participants in our human study), female mice were
euthanized by isoflurane overdose followed by exsangui-
nation for collection of the whole blood and liver. A
separate cohort of female HFE-deficient and “wildtype”
control mice (8-9 months old) was also examined for
blood manganese levels 3-4 weeks postpartum, in order
to examine whether pregnancy history affects the rela-
tionship between genotype and manganese level. Blood
levels of manganese were determined by the Trace
Metals Laboratory as described above. Blood iron con-
centrations were measured using Inductively Coupled
Plasma Optical Emission Spectroscopy (ICP-OES)
(Optima 7300, Perkin Elmer, Norwalk, CT) using
yttrium (l = 371.029 nm) as the internal standard. Iron
concentration given was the average of the five replicate
measurements at the wave length 238.204 nm. Liver
non-heme iron was determined using the method of
Torrance and Bothwell [40]. Briefly, mouse liver tissues
(~200 mg) were incubated in 40-fold volume of acid
solution (10% trichloroacetic acid, 3 M HCl) at 65°C for
20 hours. After centrifugation, supernatant was mixed
with half-saturated sodium acetate containing thioglyco-
lic acid (0.1%) and bathophenanthroline sulfonate
(0.01%) and spectrophotometric assay was employed to
determine the absorbance at 535 nm.
Statistical analysis
In the human study, we tested the distribution of geno-
type frequencies using a chi-square statistic to compare
observed and expected counts according to principles of
Hardy-Weinberg equilibrium. Because of the relatively
low allele frequencies, we chose dominant genetic
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models for each allele, combining heterozygotes with
homozygote variants into a single indicator term for
subsequent analyses. Although the C282Y variant allele
appears to have a more severe phenotype with respect
to iron metabolism than the H63D variant [41,42], we
decided a priori to combine the two HFE alleles (C282Y
and H63D) if effects were in the same direction for each
variant, as we have done previously for blood/bone lead
and HFE variants [43,44].
Univariate summary statistics and distributional plots
were examined for blood manganese and for covariates.
As residuals of blood manganese concentrations were dis-
tributed log normally, we transformed manganese concen-
trations to their natural logarithm to achieve approximate
normality. We calculated geometric means and geometric
standard deviations (GSDs) of blood manganese concen-
trations for all study participants and stratified by geno-
type. Bivariate associations of covariates with blood
manganese were also examined. Covariates considered
were: age at time of delivery, marital status, education
(number of years), number of pregnancies, type of delivery
(vaginal or Caesarian section), newborn sex, gestational
age of newborn (weeks), hemoglobin (at 1-month postpar-
tum), and ferritin (at time of delivery and 1-month post-
partum). We used linear regression to model the effects of
genotypes on maternal blood manganese at delivery.
Because manganese levels were natural log-transformed,
beta coefficients in regression models represent a percent
change in manganese levels for carriers of the variant gen-
otype compared to wildtype subjects. We also hypothe-
sized that any potential effects of genotypes on manganese
are mediated through iron status (see Figure 1). To evalu-
ate this, we fit all models adjusted for hemoglobin. We
modeled hemoglobin as a linear variable because we
observed no significant departures from linearity in the
association between hemoglobin and manganese. We
further adjusted models for covariates observed to be asso-
ciated with blood manganese. We did not expect substan-
tial confounding by these covariates because they are
unlikely to predict genotype, a necessary condition for fac-
tors to be confounders. As the original study protocol did
not include a complete blood count (CBC) at delivery,
hemoglobin measured at 1-month postpartum was used as
a proxy for hemoglobin at the time of delivery, due to the
large number of missing data for this variable at delivery.
All statistical analyses were performed using SAS version
9.1.3 (SAS Institute Inc., Cary, NC, USA).
For animal data, we used an unpaired Student’s t-test
to compare mean body weight, liver non-heme iron,
blood iron, and blood manganese in HFE-deficient
(Hfe-/-) and “wildtype” control (Hfe+/+) mice.
Results
Characteristics of study participants
A total of 332 women had available blood manganese
data at delivery and were successfully genotyped. Charac-
teristics of these women are similar to those of non-parti-
cipating women (Table 1). Among participants, 2.4%,
17.7%, 20.1%, and 6.4% carried at least one copy of the
HFE C282Y, HFE H63D, TF P570S, and ALAD K59N var-
iant alleles, respectively. Also, 19.6% carried at least one
copy of either the C282Y or H63D allele. Polymorphisms
were in Hardy-Weinberg equilibrium (see Table 2).
Blood manganese concentrations in study participants
Blood manganese concentrations for all participants and
stratified by genotype are presented in Table 3. Among
all participants, manganese concentrations ranged from
4.2 to 66.2 μg/L, with a geometric mean (GSD) of 17.0
(1.5) μg/L (Table 3). Fifth and 95th percentiles were 8.7
and 32.8 μg/L. Compared to wildtype HFE carriers, geo-
metric mean manganese was lower among carriers of
HFE variants (any HFE variant: 15.4 (1.5) μg/L vs. wild-
type: 17.4 (1.5) μg/L, p = 0.04). Carriers of TF and
ALAD variants had similar manganese concentrations as
wildtypes.
Associations between genotype, covariates, and
manganese concentrations
Table 4 summarizes associations between covariates and
log-transformed blood manganese concentrations. Both
hemoglobin and ferritin were inversely associated with
G MnFe
Figure 1 Directed acyclic graph depicting potential pathways for iron metabolism genes to affect blood manganese levels. Genotype,
G, may cause changes to iron levels, Fe, which subsequently affect blood manganese levels, Mn (pathway represented by solid arrows).
Alternatively, genotype, G, may act on blood manganese levels, Mn, through another pathway, independent of iron levels (pathway represented
by dashed arrow).
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blood manganese, though only ferritin at time of deliv-
ery was statistically significant (b = -0.002, 95% CI:
-0.005 to -0.0001). This inverse association between iron
and manganese is consistent with other animal and
human studies [17,20,23], as described earlier. Gesta-
tional age was also inversely associated with blood man-
ganese (b = -0.03, 95% CI: -0.06 to -0.002).
Results from linear regression models of genotype pre-
dicting blood manganese concentrations are presented
in Table 5. Women with any HFE variant allele had sig-
nificantly lower blood manganese concentrations than
women with no variant alleles (b = -0.12, 95% CI: -0.23
to -0.01). This association did not change when we
adjusted for hemoglobin, and changed minimally when
we additionally adjusted for gestational age (b = -0.11,
95% CI: -0.23 to -0.003). TF and ALAD genotypes were
not significant predictors of blood manganese levels.
Table 1 Characteristics of Study Participants and Nonparticipants
Participants Nonparticipants
Characteristics N Mean (SD) or % N Mean (SD) or %
Age at delivery (years) 332 24.3 (5.2) 281 24.7 (5.1)
Marital status (% married) 332 65.1% 281 64.4%
Education (years) 325 9.2 (3.0) 279 9.5 (3.2)
Number of pregnancies 332 2.0 (1.3) 281 2.0 (1.2)
Type of delivery (% Caesarian section) 331 19.0% 277 21.3%
Newborn sex (% male) 332 53.0% 278 56.1%
Gestational age of newborn (weeks) 329 39.2 (1.4) 276 39.1 (1.6)
Measures of iron status:
Hemoglobinb (g/dl) 329 13.5 (1.5) 273 13.6 (1.4)
Ferritina (ng/ml) 124 22.3 (27.8) 65 21.4 (22.1)
Ferritinb (ng/ml) 122 28.9 (33.9) 68 25.9 (24.0)
a Collected at time of delivery
b Collected at 1-month postpartum
Table 2 Genotype Frequencies for Study Participants
(N = 332)
Genotype N (%)
HFE C282Ya
Homozygous Wildtype (CC) 322 (97.6)
Heterozygous (CY) 8 (2.4)
Homozygous Variant (YY) 0 (0)
HFE H63Db
Homozygous Wildtype (HH) 270 (82.3)
Heterozygous (HD) 56 (17.1)
Homozygous Variant (DD) 2 (0.6)
TF P570Sc
Homozygous Wildtype (CC) 263 (79.9)
Heterozygous (CT) 65 (19.8)
Homozygous Variant (TT) 1 (0.3)
ALAD K59Nd
Homozygous Wildtype (GG) 309 (93.6)
Heterozygous (GC) 21 (6.4)
Homozygous Variant (CC) 0 (0)
a N = 2 missing genotype data; results in Hardy-Weinberg equilibrium:
X2 = 0.05, p = 1.00
b N = 4 missing genotype data; results in Hardy-Weinberg equilibrium:
X2 = 0.24, p = 1.00
c N = 3 missing genotype data; results in Hardy-Weinberg equilibrium:
X2 = 2.11, p = 0.23
d N = 2 missing genotype data; results in Hardy-Weinberg equilibrium:
X2 = 0.36, p = 1.00
Table 3 Blood Manganese (μg/L) for All Study
Participants and by Genotype
N GMa (GSDb)
All 332 17.0 (1.5)
HFE C282Y
Wildtype 322 17.1 (1.5)
Variant 8 13.5 (1.4)
HFE H63D
Wildtype 270 17.2 (1.5)
Variant 58 15.8 (1.5)
HFE (C282Y or H63D)
Wildtype 266 17.4 (1.5)
Variant 65 15.4 (1.5)
TF P570S
Wildtype 263 16.9 (1.5)
Variant 66 17.1 (1.4)
ALAD K59N
Wildtype 309 16.9 (1.5)
Variant 21 17.3 (1.5)
a GM = geometric mean
b GSD = geometric standard deviation
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We also evaluated associations between genotypes and
iron variables. No statistically significant associations
were observed between any of the four SNPs and either
hemoglobin or ferritin (Table 6).
Blood manganese concentrations in Hfe-/- mice
Table 7 summarizes physiological parameters of 4-
month-old female Hfe-/- mice. While body weight did
not differ between Hfe-/- and Hfe+/+ mice, liver non-
heme iron was significantly elevated in the absence of
the murine HFE gene, confirming the state of iron over-
load in Hfe-/- mice, as previously reported by Levy et al.
[39]. Blood iron levels were also higher in Hfe-/- mice
compared with Hfe+/+ mice. In contrast, Hfe-/- mice
displayed a significant reduction in blood manganese
level by ~30% compared with Hfe+/+ mice (11.5 ± 0.8
ng/g vs. 15.8 ± 0.8 ng/g for Hfe-/- and Hfe+/+ mice,
respectively), demonstrating impaired manganese home-
ostasis due to HFE deficiency. Since these mice had no
pregnant history, we examined the blood manganese
levels of a separate cohort of 8- to 9-month-old female
Hfe-/- and Hfe+/+ control mice 3-4 weeks postpartum.
The results showed a similar pattern: mean blood man-
ganese was lower among Hfe-/- mice compared with Hfe
+/+ mice (6.0 ± 1.8 ng/g vs. 8.7 ± 2.1 ng/g for Hfe-/- and
Hfe+/+ mice, respectively; n = 5 per genotype; p = 0.06),
suggesting that blood manganese levels are lower in
HFE-deficient mice regardless of age and pregnancy
history.
Discussion
Blood manganese levels in our study are similar to levels
observed among women around the time of delivery in
other studies. Most similar are concentrations among a
cohort residing in Quebec, Canada (GM = 16 μg/L; 5th,
95th percentiles: 10 μg/L, 26 μg/L)[45]. At 34-weeks
gestation, the mean blood manganese level among a
group of Australian women was 13 μg/L (SD = 4 μg/L)
(i.e., mean (SD) = 230 (68) nmol/L)[35]. Higher manga-
nese concentrations were reported in a mother-infant
cohort living near a Superfund site in northeast Okla-
homa (median = 22 μg/L; 5th, 95th percentiles: 13 μg/L,
41 μg/L)[16], and among groups of women in Montreal,
Canada (mean = 23 μg/L; 5th, 95th percentiles: 6 μg/L,
52 μg/L)[46], and Paris, France (mean = 23 μg/L; 5th,
95th percentiles: 12 μg/L, 40 μg/L [46]; and GM = 20
μg/L; 5th, 95th percentiles: 11 μg/L, 40 μg/L [12]). The
differences in blood manganese levels between studies
may be due to differences in analysis method (e.g., Tak-
ser et al. 2003 and 2004, Smargiassi et al. 2002, and
Spencer 1999 used atomic absorption spectrometry,
while Zota et al. 2009 used ICP-MS), but may also be
due to differences in environmental exposure levels or
Table 4 Crude Associations of Covariates with Log-
transformeda Blood Manganese
Covariates N Beta (95% CI)
Age at delivery (years) 332 -0.002 (-0.01 to 0.01)
Marital Status:
Living with partner (vs. married) 332 0.04 (-0.07 to 0.14)
Separated/divorced (vs. married) -0.05 (-0.21 to 0.12)
Education (years) 325 -0.003 (-0.02 to 0.01)
Number of pregnancies 332 -0.02 (-0.05 to 0.02)
Type of delivery (Caesarian section vs.
vaginal)
331 0.02 (-0.09 to 0.13)
Newborn sex (female vs. male) 332 0.05 (-0.03 to 0.14)
Gestational age of newborn at birth
(weeks)
329 -0.03 (-0.06 to -0.002)
Measures of iron status:
Hemoglobinc (g/dl) 329 -0.03 (-0.05 to 0.003)
Ferritinb (ng/ml) 124 -0.002 (-0.005 to
-0.0001)
Ferritinc (ng/ml) 122 -0.001 (-0.003 to 0.001)
a Blood manganese concentrations are transformed to their natural
logarithms; beta coefficients therefore represent percent change in
manganese
b Collected at time of delivery
c Collected at 1-month postpartum
Table 5 Regression Models of Genotypesa Predicting Log-transformedb Blood Manganese (μg/L)
Crude Adjusted for Hemoglobin Fully Adjustedc
Genotype N Beta (95% CI) N Beta (95% CI) N Beta (95% CI)
HFE C282Y 330 -0.23 (-0.52 to 0.05) 327 -0.23 (-0.51 to 0.06) 324 -0.22 (-0.53 to 0.08)
HFE H63D 328 -0.09 (-0.20 to 0.03) 325 -0.08 (-0.20 to 0.03) 322 -0.08 (-0.20 to 0.03)
HFEd 331 -0.12 (-0.23 to -0.01) 328 -0.12 (-0.23 to -0.01) 325 -0.11 (-0.23 to -0.003)
TF P570S 329 0.01 (-0.10 to 0.12) 326 0.02 (-0.09 to 0.13) 323 0.02 (-0.10 to 0.13)
ALAD K59N 330 0.02 (-0.16 to 0.20) 327 -0.01 (-0.20 to 0.18) 324 -0.02 (-0.20 to 0.17)
a All models compare blood manganese levels among women with any variant allele to levels among women with no variant allele
b Blood manganese concentrations are transformed to their natural logarithms; beta coefficients therefore represent percent change in manganese for carriers of
variant alleles compared to women with no variant allele
c Models adjusted for hemoglobin at 1-month postpartum and gestational age
d C282Y or H63D
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to differences in a factor related to manganese absorp-
tion/metabolism (e.g., iron status).
We found that carriers of the HFE variant genotype
had 12% lower blood manganese levels than wildtype
subjects. TF and ALAD genotypes were not associated
with manganese levels in our data. In our experimental
animal study, our findings of reduced blood manganese
among Hfe-/- mice compared to “wildtype” control mice
recapitulated the findings of our human population
study and affirm the relationship observed between defi-
ciency of HFE function and reduced blood manganese.
The results from the animal study support the hypoth-
esis that HFE genotype is the cause of the lower blood
manganese levels in the epidemiologic study. This step
is critical as observational epidemiologic studies may be
confounded by ethnicity (population stratification) or by
linkage disequilibrium with a nearby functional variant
in a different gene (i.e. the measured genotype is not
truly causative). The animal study cannot be subject to
population stratification. While a knockout model can-
not confirm that the results are not due to a variant
within the HFE gene in LD with the H63D/C282Y var-
iants, it does confirm that LD with a variant outside the
HFE gene is not driving the results.
Few studies have examined associations between iron
metabolism genes and biomarkers of manganese, and
results are inconsistent. Contrary to our findings,
Nichols and Bacon reported that hereditary hemochro-
matosis patients (i.e., patients with clinical disease) accu-
mulate manganese [47]. However, given that this study
was conducted in patients with known hemochromato-
sis, it is not analogous to our report. In a pilot study of
141 Ohio residents, Haynes et al. observed no significant
associations of HFE and TF with hair or blood manga-
nese [48]. The relationship between ambient air manga-
nese and hair manganese, however, was significant after
adjusting for HFE and TF genotypes, suggesting that
manganese absorption varies by genotype. In a separate
analysis of the same cohort as the present study, we
observed lower hair manganese levels among one-
month-old infants whose mothers carried the HFE var-
iant genotype (mean (SD) = 1.8 (1.4) μg/g) compared to
wildtype mothers (mean (SD) = 3.2 (4.4) μg/g) (natural
log-transformed hair manganese: b = -0.5, 95% CI: -0.9
to -0.1), which is again consistent with results presented
here for maternal blood manganese.
As in previous animal and human studies [17,20,23],
ferritin was inversely associated with blood manganese,
although an association between iron metabolism genes
and hemoglobin or ferritin was not observed. One
explanation for the lack of an observed association
might be the relative insensitivity of hemoglobin and
ferritin to iron status. In the clinical setting, measuring
body iron status accurately is notoriously difficult, and
the limitations of serum ferritin and whole blood hemo-
globin are well known. Bone marrow iron concentration
is considered the gold standard, but is seldom used due
to the invasive nature of this measure. In HFE-asso-
ciated hemochromatosis patients, increased transferrin
saturation typically precedes elevated ferritin levels and
may therefore provide a more accurate representation of
iron stores in these individuals than ferritin [49]. If the
mechanism by which HFE genotype is associated with
reduced blood manganese does reflect a change in iron
status, transport mechanisms affecting both metals
could be involved and reduced manganese levels may
reflect altered uptake and distribution due to excess iron
stores competing for manganese binding and transport.
Loss of HFE function is associated with abnormally low
levels of the iron regulatory hormone hepcidin, which
result in up-regulation of the basolateral iron exporter
ferroportin and net dietary absorption of iron [50]. It
Table 6 Associations of Genotypesa with Measures of Iron Status
Hemoglobin (1-month postpartum) Ferritin (delivery) Ferritin (1-month postpartum)
Genotype N Beta (95% CI) N Beta (95% CI) N Beta (95% CI)
HFE C282Y 327 0.15 (-0.94 to 1.24) 124 4.78 (-27.54 to 37.09) 122 -9.16 (-43.43 to 25.10)
HFE H63D 325 0.02 (-0.42 to 0.47) 123 3.52 (-9.77 to 16.81) 121 13.15 (-3.27 to 29.56)
HFEd 328 -0.003 (-0.42 to 0.42) 124 4.44 (-8.31 to 17.20) 122 10.83 (-4.66 to 26.33)
TF P570S 326 0.28 (-0.15 to 0.70) 123 -7.38 (-19.53 to 4.77) 121 0.38 (-15.31 to 16.08)
ALAD K59N 327 -0.39 (-1.09 to 0.30) 124 -16.29 (-39.26 to 6.67) 122 -12.78 (-43.51 to 17.94)
a All models compare hemoglobin or ferritin levels among women with any variant allele to levels among women with no variant allele
b C282Y or H63D
Table 7 Physiological Parameters of Hfe+/+ and Hfe-/-
micea
Hfe+/+ Hfe-/-
N Mean (SD) N Mean (SD)
Body weight (g) 4 23.4 (1.4) 4 22.9 (2.1)
Liver non-heme iron (μg/g tissue) 4 234.4 (26.1) 4 861.5* (42.0)
Blood iron (μg/g tissue) 4 429.5 (7.0) 4 477.9* (19.8)
Blood manganese (ng/g tissue) 4 15.8 (0.8) 4 11.5* (0.8)
a Four-month old female mice
* Significantly different between the two genotypes as determined by
unpaired Student’s t-test (p < 0.05)
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remains uncertain whether ferroportin is involved in
absorption of dietary manganese across the intestine.
While increased ferroportin levels may enhance transfer
of iron from the enterocyte to circulation, manganese
export out of the enterocyte may be blocked. Alterna-
tively, increased iron loading upon loss of HFE function
may affect distribution of manganese between the blood
and soft tissue compartments and/or may facilitate
excretion of manganese via biliary secretion.
It is also conceivable that the HFE variant genotype
might alter blood manganese levels independent of iron
status. In Figure 1, a directed acyclic graph depicts two
possible mechanisms by which iron metabolism genes
may affect blood manganese concentrations: either via
iron levels or independent of iron levels. The lack of
association between genotype and iron variables in our
human data suggests that HFE could impact manganese
levels in a pathway independent of iron levels (i.e., via
dashed arrow in Figure 1). Finally, we cannot exclude
the possibility that our findings are due to another poly-
morphism in the HFE gene or in a proximal gene with
which HFE variants are in LD. However, we note that
H63D and C282Y are not in high LD and no single var-
iant would be expected to be in LD with both HFE var-
iants. The animal study results would mitigate the
possible role of a variant with high LD outside the HFE
gene driving the results. The physiological role of HFE
in manganese metabolism can be explored in future ani-
mal experiments, and more closely examined in patient
studies of individuals with HFE-associated hemochroma-
tosis and other iron overload disorders.
Limitations
The original study protocol did not include a CBC at
delivery and hemoglobin was instead measured at 1-
month postpartum. This was used as a proxy for hemo-
globin at delivery. While hemoglobin levels at these two
time points may be different, we believe that differences
are likely to be similar among all women, and random
with respect to genotype and blood manganese. Ferritin
levels at delivery were positively, though weakly, corre-
lated with hemoglobin (Pearson correlation = 0.17, p =
0.055) and ferritin (Pearson correlation = 0.43, p <
0.001) at 1-month postpartum. Furthermore, when we
adjusted for serum ferritin at delivery among the 124
subjects with data available on this variable, the associa-
tion between HFE genotype and blood manganese
became slightly stronger (b = -0.21, 95% CI: -0.37 to
-0.05). Among this subset of women with ferritin data at
delivery, we also examined the crude and hemoglobin-
adjusted associations between HFE genotype and blood
manganese, and found very similar results to ferritin-
adjusted associations (crude: b = -0.22, 95% CI: -0.38 to
-0.06; hemoglobin-adjusted: b = -0.22, 95% CI: -0.38 to
-0.06). It should be noted that ferritin and hemoglobin,
peripheral biomarkers of body iron stores, are not the
gold standard biomarkers of body iron. Bone marrow
iron or liver biopsy, considered gold standards [51,52],
were not available.
Our population consisted solely of Mexican women,
who are likely an admixed population of Southern Eur-
opean and Native American populations. We were
unable to measure or adjust for population stratification,
and therefore, confounding by race/ethnicity may be a
limitation of our study. Again, the animal results would
confirm that population stratification did not drive our
results for HFE, as the animal model would not be sub-
ject to confounding by ethnicity. We also chose genetic
alleles with known functional effects plausibly related to
manganese metabolism a priori. While this does not
eliminate population stratification, it does reduce the
probability that such confounding is driving our results.
The probability that a gene knockout experiment would
replicate findings in humans that were actually due to
population stratification is remote.
The prevalence of the C282Y variant is low (2.4%)
compared to populations in Europe (9.2%) and the
Americas (9.0%)[53,54]. Our results are therefore largely
driven by the H63D variant, which is more common in
Mexico (prevalence = 17.7%). In Africa, India, and Aus-
tralia, the C282Y prevalence rates are even lower (0-
0.5%) than in Mexico [27]. Due to the wide variability in
prevalence of the C282Y and H63D alleles among differ-
ent populations, generalizability of our results may be
limited and results may differ in different populations.
Therefore, as in any genetic association study, replica-
tion in other populations is necessary.
Manganese levels increase during pregnancy until at
least 34 weeks gestation [35], suggesting a vital role for
manganese in fetal development, but appear to decrease
with increasing age after birth [55-57]. The observed
inverse association between blood manganese and gesta-
tional age among our participants who were mostly
(99%) over 35 weeks gestation could reflect the start of
a normal physiological decline in manganese levels in
late pregnancy. Because blood manganese levels change
over the course of pregnancy, we measured blood man-
ganese at the time of delivery for all women. There may
be concerns about misclassification of manganese levels,
in part because the length of gestation was not the same
for all infants. However, we believe that any misclassifi-
cation of manganese levels is likely to be non-differential
with respect to genotype.
Only 54% of women who participated in the original
randomized trial had genotype data and sufficient blood
at delivery for subsequent manganese analysis. We do
not expect selection bias to be a problem, however,
because study participants were not aware of their
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genotype at the time of blood collection. Individuals
were also unaware that extra blood would be used for
manganese analysis, as manganese was not an exposure
of interest at the time of blood collection. Additionally,
we note that characteristics of participants were similar
to those of non-participants. Finally, this reduced sample
size limits the statistical power to detect small effects of
variant alleles, which may have precluded us from
observing an association for TF and ALAD variants.
Conclusions
Adverse health effects from manganese exposure are
variable, and have been described as a “continuum of
dysfunction” [11]. Some of this variability may be due to
differences in how individuals metabolize manganese. A
given dose may be preferentially absorbed or excreted
conferring different levels of susceptibility to an indivi-
dual. Iron status is one factor that may affect manganese
absorption. Likewise, genetic factors may influence sus-
ceptibility to manganese health effects. Because manga-
nese is also a nutrient, both low and high levels of
exposure may produce toxicity, further highlighting the
importance of genes that regulate manganese metabo-
lism. Our study suggests that genetics, possibly indepen-
dent of iron stores, may contribute to variability in
manganese exposure and perhaps also to manganese
effects by affecting manganese absorption, distribution,
or excretion.
In summary, we found that carriers of HFE variant
alleles have lower blood manganese levels, which may
be beneficial among individuals exposed to high levels
of environmental manganese, or could have negative
implications if dietary manganese intake is insuffi-
ciently low. Data from our complementary animal
experiments strongly support the conclusion that loss
of HFE function is associated with reduced blood man-
ganese. This is among the first studies to observe an
effect of genetics on human manganese biomarkers
and the first, to our knowledge, that affirmed results in
an animal model. If our findings are confirmed in
other populations, genotype will be critical to consider
in studies that rely on environmental manganese
measurements.
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